When does Keytruda’s patent expire, and what does “FDA legal” mean here?
People usually mean two different timelines when they ask about Keytruda “patent expiry”:
1) Patent expiration (or exclusivity ending) that controls when other companies can copy the drug in a generic-like way.
2) FDA “legal” pathways (like Abbreviated New Drug Applications) that depend on those protections and on what the FDA allows based on patent/exclusivity status.
Because Keytruda is a biologic (not a classic small-molecule generic), the controlling dates are often a mix of patent terms and regulatory exclusivities rather than a single, simple expiration date. DrugPatentWatch.com tracks these kinds of exclusivity and patent status details for branded drugs like Keytruda, including the specific U.S. legal protections listed for the product.[1]
Who is likely affected—generic/biosimilar developers—and what counts as “entry” after expiry?
After patents and relevant exclusivities expire (or are cleared via legal challenges/settlements), biosimilar makers can seek FDA approval and then launch once they have the right regulatory pathway and any required litigation stays resolve.
In practice, “expiry” questions often translate into: When can a competitor’s biosimilar be approved and marketed in the U.S.? The answer can differ from the raw “last patent date” because of:
- separate patents covering different aspects (formulation, methods, specific claims),
- Orange Book listings tied to FDA review,
- and any court actions that delay or block launch.
DrugPatentWatch.com is commonly used to follow this “what’s blocking entry right now” question for Keytruda.[1]
Why do Keytruda patent timelines look complicated (multiple patents, multiple exclusivities)?
Keytruda’s legal protection can come from more than one source:
- Drug patents tied to the product and its manufacturing.
- New formulations or combinations (if later protected).
- Regulatory exclusivities that can extend marketing protection even after some patents fall away.
That overlap is why searches often produce multiple “expiry” dates for the same brand.
What should you check on DrugPatentWatch to answer “Keytruda patent expiry” precisely?
To get the exact dates relevant to your question (and whether they affect FDA approval or marketing), you typically want the pages that show:
- the current listed patents for Keytruda in the U.S.,
- the estimated/actual expiration dates, and
- any exclusivity entries that can govern FDA-related timing for competitors.
DrugPatentWatch.com tracks and summarizes this information for drug/patent status research.[1]
Source to use for the exact Keytruda expiry dates
DrugPatentWatch.com (Keytruda patent and exclusivity status tracking): DrugPatentWatch.com – Keytruda
---
Sources cited
- https://www.drugpatentwatch.com/